Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B

Inclusion Criteria: * Male or female 16 to 65 year of age * Documented CHB defined by detectable serum HBsAg and serum HBV DNA level * Willing and able to comply with the study drug regimen * Written informed consent before any assessment Exclusion Criteria: * Patient has a history of/or clinical signs/symptoms of hepatic decompensation * Patient has a history of HCC or findings suggestive of possible HCC * Patient has received treatment of nucleoside or nucleotide drugs whether approved or investigational at any time * History of hypersensitivity to any of the drugs (telbivudine) or to drugs of similar clinical classes * Patient has received IFN or other immunomodulatory treatment with 12 months before screening * Previous treatment history with NRTIs Other protocol-defined inclusion/exclusion criteria may apply.